Table 4 Assessment of the pharmacist’s role in patient’s counseling and education about the prescribed antimotility medication
Educational parameter | Scenario 1 | Scenario 2 | |||||
|---|---|---|---|---|---|---|---|
Pre-application (N = 13) | Post-application (N = 15) | P value | Pre-application (N = 11) | Post-application (N = 15) | P value | ||
Initial dose | Mentioned appropriately N(%) | 8 (61.54) | 13 (86.67) | 0.069 | 6 (54.55) | 15 (100) | 0.007 |
Mentioned inappropriately N(%) | 5 (38.46) | 1 (6.67) | 4 (36.36) | 0 (0) | |||
Not mentioned N(%) | 0 (0) | 1 (6.67) | 1 (9.09) | 0 (0) | |||
Dosing frequency | Mentioned appropriately N(%) | 8 (61.54) | 13 (86.67) | 0.069 | 8 (72.73) | 15 (100) | 0.063 |
Mentioned inappropriately N(%) | 5 (38.46) | 1 (6.67) | 2 (18.18) | 0 (0) | |||
Not mentioned N(%) | 0 (0) | 1 (6.67) | 1 (9.09) | 0 (0) | |||
How long to take the medication (TTS) | Mentioned appropriately N(%) | 2 (15.38) | 12 (80) | 0.001 | 2 (18.18) | 15 (100) | 0.000 |
Mentioned inappropriately N(%) | 5 (38.46) | 0 (0) | 2 (18.18) | 0 (0) | |||
Not mentioned N(%) | 6 (46.15) | 3 (20) | 7 (63.64) | 0 (0) | |||
Possible medication side effects | Mentioned appropriately N(%) | 0 (0) | 12 (80) | 0.000 | 0 (0) | 13 (86.67) | 0.000 |
Mentioned inappropriately N(%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
Not mentioned N(%) | 13 (100) | 3 (20) | 13 (100) | 2 (13.33) | |||
Overall patient education and counseling (dose, dosing regimen, side effect, TTS) (Max = 4 points) | All information that was given to the patient | 2.62 ± 0.51 | 3.60 ± 0.63 | 0.006 | 2.25 ± 0.62 | 3.87 ± 0.35 | 0.004 |
Information that was given to the patient in a correct way | 1.46 ± 1.05 | 3.53 ± 1.06 | 0.002 | 1.42 ± 1.16 | 3.87 ± 0.35 | 0.005 | |
Appropriate patient education and counseling N(%) | 0 (0.0) | 10 (66.67) | 0.000 | 0 (0.0) | 13 (86.67) | 0.000 | |